support, which is the form of social support associated with adherence to medical treatment. 6 Clinician skin examination and SSE operate in synergy with the physician encouraging SSE and if something suspicious results from the SSE the patient returns to the physician.
A limitation of the current study is the short-term followup of our remote skills training. The long-term benefits of remote training of pairs needs further evaluation to determine if SSE is sustained, the rate of biopsy of concerning moles, and the results of those biopsies.
While other studies have included partners in an educational session and found social support of the partner was a strong predictor of SSE self-efficacy, 7 our group differs in providing a structured skills training program in partner assisted skin self-examination with longitudinal assessment of a range of outcomes. 1 Our findings support integration of structured evidence-based SSE training of atrisk patients into the fabric of clinical care.
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Research Letter
Dear Editor,
Elevated serum interleukin-29 levels in patients with
Henoch-Sch€ onlein purpura
Henoch-Sch€ onlein purpura (HSP), also known as immunoglobulin A vasculitis, is the most common systemic vasculitis in childhood and is characterized clinically by 3 However, to the best of our knowledge, the association of IL-29 and HSP is completely unknown.
To explore the role of IL-29 in the pathogenic mechanism of HSP, this study investigated the IL-29 serum levels in 38 patients (17 males and 21 females) meeting the diagnostic criteria for HSP, 4 23 patients with atopic dermatitis (AD), and 34 age-and gender-matched controls by enzyme-linked immunosorbent assay. A detailed history and physical examination for each patient were obtained and listed in Tables S1 and S2. All patients and controls were not treated 2 weeks before this study. A semi-quantitative scoring system was used to evaluate the activity and severity of HSP according to our previous publication. 5 Twenty HSP patients were treated with oral antihistamines and vitamin C, with serum samples collected during the convalescent stage. As shown in Fig. 1a , patients with HSP in acute stage have significantly higher IL-29 serum levels (37.81 23.1 pg/ml)than AD patients (24.64 AE 14.31 pg/ml) or control subjects (22.31 AE 11.32 pg/ml). Moreover, serum IL-29 fell in 20 HSP patients during the convalescent stage ( Fig. 1b ; P = 0.001). Furthermore, as presented in Fig. 1c , serum IL-29 levels in HSP patients in acute stage correlated with severity score of this disease (r = 0.427, P = 0.008).
In addition, we investigated the mRNA expression of IL-29 in peripheral blood mononuclear cells (PBMCs) from HSP patients by real-time quantitative PCR. As shown in Fig. 2 , the mRNA levels of IL-29 in PBMCs from HSP patients were markedly higher than those in control group (P = 0.002). We suggest that PBMCs might be a source of excessive production of IL-29, and contribute to the increased serum IL-29 levels in HSP patients. Furthermore, increasing evidence indicates that IL-29 can activate the Janus kinase/signal transducers and activators of transcription pathway and affect the production of cytokines. For example, Srinivas and colleagues 6 reported that IL-29
can act as an inhibitor of Th2 response, and down-regulate IL-13 production in human PBMCs. On the other hand, IL-29 can induce the secretion of IFN-c in healthy PBMCs, 7, 8 up-regulate the levels of IL-6, IL-8 and IL-10 in We suggest that IL-29 may serve as a pro-inflammatory cytokine and play a role in the pathogenesis of HSP. 
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The effectiveness of combination therapy with 308-nm excimer laser in vitiligo in Han Chinese People
Vitiligo is an acquired pigmentary disorder characterized by white macules that result from a loss of functioning melanocytes. 1 Currently various therapeutic modalities are available for the treatment of vitiligo, but these are reported to have limited efficacy with a relatively high occurrence of adverse events. There remains a demand for new therapies. 2, 3 Recently, 308-nm excimer laser has been reported to promote the proliferation and migration of melanocytes when used as an adjunt vitiligo treatment. [4] [5] [6] An advantage of 308-nm excimer laser over ultraviolet light, is the reduced risk of carcinogenesis. [7] [8] [9] We compare the efficiency of 308-nm excimer laser with combined therapy in vitiligo in Han Chinese adults. Patients seeking treatment for vitiligo (June 2016-2017) were approached for enrollment in the study. Eligible patients were 30-60 years old, with a body surface area involvement of <20%. Any concomitant treatment for vitiligo was restricted for 4 weeks before this study commenced. This study was approved by committee of our hospital. A total of 152 patients were randomly divided into three treatment groups: tacrolimus group: lesions of vitiligo received excimer laser twice per week with combination of 0.1% tacrolimus ointment twice daily; halometasone group: vitiligo lesions received excimer laser twice per week with combination of halometasone cream twice daily; excimer laser only group: vitiligo lesions received excimer laser twice per week only. Demographic features between these three groups were matched (Table 1) .
Once a subject's minimal erythema dose (MED) was determined, the target lesions were irradiated every 72 h for 12 weeks. The initial radiation dose was adjusted according to the extent of the erythema after the previous treatment. If the erythema lasted for 24-48 h, the dose remained the same; if it lasted <24 h, the dose was increased by 25-50 mJ/cm 2 ; if it lasted for 48-60 h, the dose was reduced 25-50 mJ/m 2 ; if the patient reported erythema and blisters, irradiation was suspend until resolution of symptoms and the dose was reduced 100mJ/m2 in next treatment. The treatment efficacies for all subjects were evaluated by a dermatologist blinded to treatment allocation after 6 and 12 weeks. Treatment efficacy was assessed using a visual grading system: no or weak effect, 0-25% repigmentation; moderate effect, >25-50% repigmentation; excellent effect, >50-99% repigmentation; and complete effect, 100% repigmentation. The data were analyzed by software SPSS 16.0. Data were described by percentage and Chi-square. In all tests, P < 0.05 was considered as the significance level. All patients completed the 12-week treatment period (Table 2 and 3 ). The effective rates of repigmentation on face and neck, and trunk were higher than limb and acral (v 2 = 6.952, P = 0.008 face and neck vs. limb; v 2 = 11.284, P = 0.001 face and neck vs. acral; v 2 = 6.496, P = 0.011 trunk vs. limb; v 2 = 10.794, P = 0.001 trunk vs. acral). There was no significant difference between face and neck lesions and trunk lesions. The effective rates of repigmentation in the two combined therapy groups were both higher than 308-nm excimer laser only treatment (v 2 = 11.749, P = 0.001 tacrolimus + laser vs. laser only; v 2 = 21.356, P < 0.001 halometasone + laser vs. laser only).
Our study shows that patients with vitiligo who received combined treatment with halometasone and excimer laser had more satisfactory repigmentation in comparison with individuals who only underwent 308-nm excimer laser therapy, even little higher than the patients who received combined treatment with tacrolimus and excimer laser therapy, especially on face and neck and trunk sites. 
